Zobrazeno 1 - 10
of 33
pro vyhledávání: '"M Sarobe Carricas"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A Egüés Lugea, A Rodríguez Esquíroz, B Fernandino Zubieta, B Galarraga Iñarra, M Timoneda Company, R Escobedo Romero, M Sarobe Carricas
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb309a37bbb3733d07f6048007d2140b
https://doi.org/10.1136/ejhpharm-2023-eahp.305
https://doi.org/10.1136/ejhpharm-2023-eahp.305
Autor:
A Rodríguez Esquíroz, C Leralta González, M Jiménez Meseguer, ÁL Salcedo Mingorranz, B García Díaz, M Sarobe Carricas, MF Hurtado Gómez
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af7ba2339822d1813455182b0301d034
https://doi.org/10.1136/ejhpharm-2023-eahp.237
https://doi.org/10.1136/ejhpharm-2023-eahp.237
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76e08d599958fc10de7bf20632a4e80b
https://doi.org/10.1136/ejhpharm-2023-eahp.225
https://doi.org/10.1136/ejhpharm-2023-eahp.225
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46f92fe5f9ba2e805b21a8c1e5799fe4
https://doi.org/10.1136/ejhpharm-2023-eahp.54
https://doi.org/10.1136/ejhpharm-2023-eahp.54
Autor:
A Rodríguez Esquíroz, NG Lizama Gómez, AM Gascón Villacampa, M Pío Asín, L Lorza Gil, DP Millacoy Austenrritt, M Sarobe Carricas
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b71ddef5cc678634d3b1d1f3580eedb1
https://doi.org/10.1136/ejhpharm-2023-eahp.133
https://doi.org/10.1136/ejhpharm-2023-eahp.133
Autor:
D Tejada Marín, A Rodriguez Esquiroz, D Fresán Restituto, R San Miguel Elcano, A Cedeño Veloz, V Roncal Belzunce, N Martinez Velilla, M Sarobe Carricas
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::115657ea5dea5de05e6d90dafccc17b3
https://doi.org/10.1136/ejhpharm-2022-eahp.142
https://doi.org/10.1136/ejhpharm-2022-eahp.142
Autor:
M Sarobe Carricas, J.J. Elizondo Armendáriz, G Pinilla Lebrero, A Rodríguez Esquíroz, L Ulacia Epelde, I Ortega Belio, D Fresan Restituto, D Tejada Marín, M Calvo Arbeloa, JA Illodo Becerra
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend the optimisation of the nutritional status of patients with SARSCoV- 2 infection through dietary advice and/or oral nutritional suppleme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::285f71b0f54b9e0c7f5c90bfc2047417
https://doi.org/10.1136/ejhpharm-2021-eahpconf.192
https://doi.org/10.1136/ejhpharm-2021-eahpconf.192
Autor:
G Pinilla Lebrero, E Lacalle Fabo, P Aldave Cobos, L Ulacia Epelde, JA Illodo Becerra, J.J. Elizondo Armendáriz, D Fresan Restituto, M Sarobe Carricas, J Polo García, M Calvo Arbeloa
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Severe uncontrolled asthma is characterised by poor control despite treatment with inhaled glucocorticoids (IGC) and beta2 adrenergic agonists (LABA) at high doses, and/or oral glucocorticoids (OGC). This type of asthma comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7f3ac6438d21ea68b69b9fd181c409f
https://doi.org/10.1136/ejhpharm-2020-eahpconf.243
https://doi.org/10.1136/ejhpharm-2020-eahpconf.243
Autor:
J Polo García, M Sarobe Carricas, D Tejada Marín, A Arrondo Velasco, G Pinilla Lebrero, J.J. Elizondo Armendáriz, A Rodríguez Esquíroz, M Calvo Arbeloa
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Inflammatory bowel disease (IBD) is a group of chronic relapsing diseases. In the past 10 years, biologic agents such as adalimumab, golimumab and ustekinumab have meant a great change in their therapy. Correct adherence pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3ca1fdd343df2881a7df94459413f85
https://doi.org/10.1136/ejhpharm-2020-eahpconf.213
https://doi.org/10.1136/ejhpharm-2020-eahpconf.213